Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview.

Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview.
复制标题

DOI:
10.3390/ijms222111825
复制
发表时间:
2021-10-31
影响因子:
5.6
通讯作者:
Buzzaccarini G
Buzzaccarini G
中科院分区:
生物学2区
文献类型:
--
作者:
Gullo G;Etrusco A;Cucinella G;Perino A;Chiantera V;Laganà AS;Tomaiuolo R;Vitagliano A;Giampaolino P;Noventa M;Andrisani A;Buzzaccarini G

文献摘要

参考文献

被引文献

相似文献

子宫内膜癌(EC)是一种严重影响妇女生活质量的有害疾病。虽然积极的干预措施应考虑治疗高级别EC,保守的方法应考虑妇女希望怀孕。在这种情况下,我们提出了一个关于EC生育力保留方法的最新技术水平的概述。I型EC在低阶段是唯一的组织学类型,可以解决与生育力保留的方法。此外,不应发现子宫肌层和/或附件侵犯,也不应累及淋巴管间隙。关于药物靶点,孕激素,特别是醋酸甲羟孕酮(MPA)或醋酸甲地孕酮(MA),是早期EC保守治疗中最常用的药物。二甲双胍的使用和宫腔镜评估仍在争论中,尽管有希望的结果。应特别严格和紧迫的关注后续和心理健康的妇女,特别是因为双重有害的损害:EC和EC相关的不孕症的后果。
Endometrial cancer (EC) is a deleterious condition which strongly affects a woman’s quality of life. Although aggressive interventions should be considered to treat high-grade EC, a conservative approach should be taken into consideration for women wishing to conceive. In this scenario, we present an overview about the EC fertility-sparing approach state of art. Type I EC at low stage is the only histological type which can be addressed with a fertility-sparing approach. Moreover, no myometrium and/or adnexal invasion should be seen, and lymph-vascular space should not be involved. Regarding the pharmaceutical target, progestins, in particular medroxyprogesterone acetate (MPA) or megestrol acetate (MA), are the most employed agent in conservative treatment of early-stage EC. The metformin usage and hysteroscopic assessment is still under debate, despite promising results. Particularly strict and imperious attention should be given to the follow-up and psychological wellbeing of women, especially because of the double detrimental impairment: both EC and EC-related infertility consequences.
DOI: 10.3390/ph14060504
发表时间: 2021-05-25
期刊: Pharmaceuticals (Basel, Switzerland)
影响因子: --
作者:
Gambioli R;Forte G;Buzzaccarini G;Unfer V;Laganà AS
通讯作者: Laganà AS
DOI: 10.1158/1055-9965.epi-07-2686
发表时间: 2008-04-01
影响因子: 3.8
作者:
Gunter, Marc J.;Hoover, Donald R.;Strickler, Howard D.
通讯作者: Strickler, Howard D.
DOI: 10.1136/ijgc-2018-000036
发表时间: 2019-01-01
影响因子: 4.8
作者:
Chae, Su Hyun;Shim, Seung-Hyuk;Kang, Soon-Beom
通讯作者: Kang, Soon-Beom
DOI: 10.1016/j.metabol.2008.05.008
发表时间: 2008-10-01
影响因子: 9.8
作者:
Cheang, Kai I.;Baillargeon, Jean-Patrice;Nestler, John E.
通讯作者: Nestler, John E.
DOI: 10.1507/endocrj.ej13-0423
发表时间: 2014-02-01
期刊: ENDOCRINE JOURNAL
影响因子: 2
作者:
Heimark, Douglas;McAllister, Jan;Larner, Joseph
通讯作者: Larner, Joseph